Walgreens Boots Alliance, Inc. completed the acquisition of remaining 45% stake in CareCentrix, Inc. for approximately $380 million.
March 30, 2023
Share
Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million on October 11, 2022. The company will continue as a distinct business and brand within Walgreens following the full acquisition. CareCentrix CEO John Driscoll to join WBA to lead U.S. Healthcare, including Walgreens Health and will assume a new role as executive vice president and president. CareCentrix Chief Financial Officer, Steve Horowitz, will assume the role of CareCentrix CEO. The acquisition is subject to limited customary closing conditions and is expected to close by March 2023. As of January 5, 2023, the acquisition is expected to close in the third quarter of fiscal 2023. Vadim M. Brusser, Steven A. Newborn of Weil, Gotshal & Manges LLP acted as legal advisor to Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of remaining 45% stake in CareCentrix, Inc. for approximately $380 million on March 31, 2023.
Walgreens Boots Alliance, Inc. specializes in the distribution of pharmaceutical products. Net sales break down by activity as follows:
- retail distribution (87.2%): selling prescription drugs, OTC medicines, beauty and cosmetic products, etc. in the United States (90.9% of net sales) and internationally (9.1%). At the end of August 2023, the activity is carried out through 13,532 outlets (of which 8,706 located in the United States, Puerto Rico and the US Virgin Islands), and through the Internet;
- wholesale distribution (8.1%).
The remaining sales (4.7%) are from the healthcare
Net sales break down geographically as follows: the United States (84%), Germany (8.1%), the United Kingdom (6.5%) and other (1.4%).
WALGREENS BOOTS ALLIANCE, INC. 
